Coffee and registration
Welcome & opening address from the chair
Secretary General, Irish Pharmacy Union
Opening Discussion: Ireland in the eye of the storm? What’s the outlook for the industry in the new economic and political landscape?
Is Ireland heading for a perfect storm caught between Brexit and the new American administration’s plans for corporate tax and greater protectionism?
- How will Brexit play out in the months and years ahead?
- What are the business, research and regulatory implications?
- What’s the potential impact on FDI of President Trump’s tax plans and his particular plans for the US pharma industry?
Head of Biopharmaceuticals and Food, IDA Ireland
Jim Power Economics
Partner, Pharmaceuticals and Life Sciences, PwC
Confronting pharma’s reputation challenge… one company’s story
Vice President and General Manager, GSK Pharmaceuticals Ireland
Panel Discussion: We know the price of medicines, but what about the value?
Medicine pricing has become a hot button issue across the world, as healthcare systems already strained by demographic shifts and funding issues struggle to cope with the prices of some new innovative medicines. But, are we in danger of focusing too much on price at the cost of value?
- How should the value of life sciences products be defined?
- Are premium prices the only way to sustain innovation?
- What alternative payment and risk-sharing models can be created to make medicines more affordable?
- How to involve patients more in decisions about access and pricing.
- How will pharma companies become part of the solution in helping cash-strapped healthcare systems?
CEO, Teva Pharmaceuticals
National Director, Primary Care, Health Services Executive
CEO, The Irish Platform for Patient Organisations, Science and Industry
CEO, Irish Pharmaceutical Healthcare Association (IPHA)
International Keynote Address: Biosimilars Outlook: What drives success for producers and payers?
The promise of biosimilars is clinical performance at a lower price so how can payers get long-term savings? What matters most to biosimilar developers? How do we design the right clinical development programme for biosimilars? How to maximise uptake? How to create trust and build confidence among patients and doctors? Richard, who has over 10 years experience of biosimilars, answers your questions.
Dr Richard Littlewood
CEO and Founder, applied strategic, UK
Panel Discussion: Biopharma 2027: What’s next for biotech?
Our panel of industry stakeholders give their insights on what’s in store for biopharma in the next decade.
Dr. Jayne Crowe
Director of Human Products Authorisation and Registration, Health Products Regulatory Authority (HPRA)
Director, Biopharmachem Ireland (Ibec)
Professor Luke O'Neill
Chair of Biochemistry, Trinity College Dublin
Managing Director, AXIS Consulting Ltd